<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: The PI3K/AKT/mTOR pathway is frequently dysregulated in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> and inhibition of mTOR has demonstrated the ability to modulate pro-survival pathways </plain></SENT>
<SENT sid="1" pm="."><plain>As such, we sought to determine the ability of the mTOR inhibitor everolimus to potentiate the antitumor effects of irinotecan in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>EXPERIMENTAL DESIGN: The combinatorial effects of everolimus and irinotecan were evaluated in vitro and in vivo in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines harboring commonly found mutations in PIK3CA, KRAS and/or BRAF </plain></SENT>
<SENT sid="3" pm="."><plain>Pharmacokinetically-directed dosing protocols of everolimus and irinotecan were established and used to assess the in vivo antitumor effects of the agents </plain></SENT>
<SENT sid="4" pm="."><plain>At the end of treatment, 3-6 tumors per treatment arm were harvested for biomarker analysis by NMR metabolomics </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Everolimus and irinotecan/SN38 demonstrated synergistic anti-proliferative effects in multiple <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines in vitro </plain></SENT>
<SENT sid="6" pm="."><plain>Combination effects of everolimus and irinotecan were determined in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft models</z:e> using clinically-relevant dosing protocols </plain></SENT>
<SENT sid="7" pm="."><plain>Everolimus demonstrated significant <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> inhibition alone and when combined with irinotecan in HT29 and HCT116 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> xenografts </plain></SENT>
<SENT sid="8" pm="."><plain>Metabolomic analysis showed that HT29 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were more metabolically responsive than HCT116 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Everolimus caused a decrease in glycolysis in both <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> types whilst irinotecan treatment resulted in a profound accumulation of <z:chebi fb="23" ids="18059">lipids</z:chebi> in HT29 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> indicating a cytotoxic effect </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Quantitative analysis of <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> and metabolomic data showed that the combination of everolimus and irinotecan was more beneficial in the BRAF/PIK3CA mutant HT29 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> xenografts, which had an additive effect, than the KRAS/PIK3CA mutant HCT116 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> xenografts, which had a less than additive effect </plain></SENT>
</text></document>